Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan C Oosterwijk

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
British Journal of Cancer|March 7, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
European Urology|September 21, 2019
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation CarriersElizabeth C Page, Elizabeth K Bancroft, Mark N Brook, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.
Breast Cancer Research and Treatment|November 1, 2016
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3Yosr Hamdi, Penny Soucy, Karoline B Kuchenbaeker, et al.
Breast Cancer Research : BCR|February 22, 2012
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriersAntonis C Antoniou, Karoline B Kuchenbaecker, Penny Soucy, et al.
Breast Cancer Research : BCR|May 1, 2015
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersSophie Blein, Claire Bardel, Vincent Danjean, et al.
The New England Journal of Medicine|January 20, 2021
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women, Leila Dorling, Sara Carvalho, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
British Journal of Cancer|March 7, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
European Urology|September 21, 2019
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation CarriersElizabeth C Page, Elizabeth K Bancroft, Mark N Brook, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.
Breast Cancer Research and Treatment|November 1, 2016
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3Yosr Hamdi, Penny Soucy, Karoline B Kuchenbaeker, et al.
Breast Cancer Research : BCR|February 22, 2012
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriersAntonis C Antoniou, Karoline B Kuchenbaecker, Penny Soucy, et al.
Breast Cancer Research : BCR|May 1, 2015
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersSophie Blein, Claire Bardel, Vincent Danjean, et al.
The New England Journal of Medicine|January 20, 2021
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women, Leila Dorling, Sara Carvalho, et al.
Pageof 10